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ABSTRACT: (+)-Ryanodine is a natural product modulator of
ryanodine receptors, important intracellular calcium ion
channels that play a critical role in signal transduction leading
to muscle movement and synaptic transmission. Chemical
derivatization of (+)-ryanodine has demonstrated that certain
peripheral structural modiﬁcations can alter its pharmacology,
and that the pyrrole-2-carboxylate ester is critical for high
aﬃnity binding to ryanodine receptors. However, the structural
variation of available ryanodine analogues has been limited by
the challenge of site-speciﬁc functionalization of semisynthetic intermediates, such as (+)-ryanodol. Here we report a synthetic
strategy that provides access to (+)-ryanodine and the related natural product (+)-20-deoxyspiganthine in 18 and 19 steps,
respectively. A key feature of this strategy is the reductive cyclization of an epoxide intermediate that possesses the critical
pyrrole-2-carboxylate ester. This approach allows for the direct introduction of this ester in the ﬁnal stage of the synthesis and
provides a framework for the synthesis of previously inaccessible synthetic ryanoids.
The ryanodine receptors (RyRs) are large, tetramericprotein assemblies that mediate rapid Ca2+ release from
the sarco/endoplasmic reticulum to the cytoplasm, thereby
triggering numerous physiological processes, including excita-
tion−contraction coupling (ECC).1,2 There are three mamma-
lian RyR isoforms (RyR1, RyR2, and RyR3) that are expressed
primarily in muscle and brain tissue, although the expression
levels of each depend on the tissue.1 Several diseases have been
traced to aberrant RyR function:3 for example, malignant
hypothermia and central core disease are disorders of skeletal
muscle that result from mutations in RyR1,4 whereas mutations
in RyR2 have been linked to inherited arrhythmogenic cardiac
diseases.5 In addition, dysregulation of RyR2- and RyR3-
mediated calcium release has been linked to the pathogenesis of
Alzheimer’s disease.6,7
The ryanodine receptors derive their name from a natural
product, (+)-ryanodine (1) (Figure 1), a tritiated version of
which was used as a radiochemical tag for their isolation and
puriﬁcation.8,9 1 is a structurally complex diterpenoid that was
ﬁrst isolated in 1948 by Folkers and co-workers from Ryania
speciosa Vahl, an insecticidal shrub native to Central and South
America.10 Although a molecular formula was provided in the
initial report, two decades of chemical degradation and
derivatization studies were required before the structure was
correctly assigned.11−13 Since the isolation of 1, several
structurally related natural products that share a common
carbocyclic core but vary in peripheral oxidation, such as
(+)-spiganthine (2) and (+)-20-deoxyspiganthine (3),14,15 have
also been identiﬁed as modulators of RyR function.
(+)-Ryanodine binds with high aﬃnity to the conducting
state of RyRs and is a valuable tool that has been used to
interrogate the functional state of these ion channels.16
Notably, the hydrolysis product (+)-ryanodol (4) binds
∼1700 and ∼800 times more weakly than 1 to RyRs derived
from rabbit skeletal and cardiac tissue, respectively.17 This
structure−activity relationship (SAR) implicates the C3
pyrrole-2-carboxylate ester as a critical structural component
for receptor binding. Unfortunately, the challenge of modifying
(+)-ryanodol (or appropriately protected derivatives) at C3 has
hampered the synthesis of ester analogues that would provide a
more detailed SAR. In this report, we describe an 18-step
chemical synthesis of ryanodine that overcomes this challenge
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Figure 1. Ryanodine, ryanodol, and related natural products.
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by directly incorporating the C3 pyrrole-2-carboxylate ester at a
late stage. We also demonstrate that the same approach can be
used to prepare the related natural product (+)-20-
deoxyspiganthine (3) in 19 steps. The strategy described here
will serve as a platform for the synthesis and study of previously
inaccessible ryanoids as tools to investigate and modulate RyR
function.
Previous synthetic eﬀorts toward the ryanoids have focused
primarily on the preparation of the deacylated compound,
(+)-ryanodol (4), with the ﬁrst chemical synthesis reported by
Deslongchamps and co-workers in 1979 (37 linear steps).18−22
Deslongchamps’s synthesis was guided by the discovery that
(+)-anhydroryanodol (5) could be converted to 4 in two
steps.18 Deslongchamps, Ruest, and co-workers,23 as well as an
independent team lead by Casida,24 subsequently went on to
prepare a number of semisynthetic derivatives of 1 and 4 for
use in pharmacological studies. These investigations revealed a
key challenge: the diﬃculty of converting (+)-ryanodol to
(+)-ryanodine. This challenge is one of chemoselectivity, in
that a site-speciﬁc acylation of a molecule containing seven
hydroxyl groups (including the C15 hemiacetal) is required;
this is further exacerbated by the fact that the sterically
encumbered C3 alcohol is much less intrinsically reactive than
the surrounding O−H groups.
The question of whether 4 can be converted to 1 was ﬁnally
answered in recent studies by Inoue and co-workers.25 Having
completed a 35 step synthesis of (±)-ryanodol in 2014,26 they
subsequently determined that it can be advanced in 4 steps to
an intermediate in which all but the C3 alcohol is protected.
Although this compound could not be directly coupled with
pyrrole-2-carboxylic acid (or its derivatives), it could be
esteriﬁed with N,N-di(tert-butoxycarbonyl)glycine, and elabo-
rated in an additional 5 steps to 1.25 In sum, the conversion of 4
to 1 required ten synthetic steps. Alternatively, Inoue and co-
workers demonstrated that a synthetic precursor to 4 could be
advanced directly to 1, allowing access to ryanodine in 42 linear
steps.27,28
We recently described a 15-step synthesis of (+)-ryanodol
from the terpene (S)-pulegone.29 The synthesis was enabled by
the expedient, gram scale preparation of tetracycle 6, which can
be oxidized using SeO2, then triﬂated, to give either of two
oxidation products, 7 or 8 (Figure 2A). In considering how to
translate our synthesis of 4 to a synthesis of 1, our guiding
strategic objective was to incorporate the pyrrole-2-carboxylate
ester directlyrather than building it from a glycinate
ester25,28by an esteriﬁcation reaction in the ﬁnal stage of
the synthesis. Given the challenges encountered by others when
trying to acylate 4, or appropriately protected derivatives of 4,
we decided to target the acylation of a protected derivative of
(+)-anhydroryanodol (5) (Figure 2B).
This decision was driven by the hypothesis that the C3
hydroxyl group of 5 is less sterically hindered, and by the fact
that 5 presents two fewer hydroxyl groups than 4, thereby
simplifying the chemoselectivity challenge. Although this
approach was considered advantageous from the perspective
of the C3-acylation, it presents its own challenge in that the
pyrrole-2-carboxylate ester would need to survive the required
epoxidation of the C1−C2 alkene (10 → 9), as well as the
reductive ring closure event (9 → 1). The reductive cyclization
of anhydroryanodol epoxide intermediates bearing C3 ester
functionality (e.g., 9) had not been reported previously. Finally,
we hoped to adapt the chemistry developed for the synthesis of
(+)-ryanodine to the synthesis of (+)-20-deoxyspiganthine (3),
beginning from 8 (Figure 2A), with minimal amounts of
reaction reoptimization. Although this study would focus on the
synthesis of 1 and 3, we anticipated that, if successful, it would
ultimately enable the incorporation of previously inaccessible
pyrrole esters at C3 through simple acylation chemistry, thus
allowing access to new synthetic ryanoids.
The synthesis of ryanodine (1) commenced with tetracycle
12, accessible in 11 steps from (S)-pulegone (11) and prepared
in gram quantities on a single pass through the sequence
(Scheme 1).29 Prior studies have shown that the C4 and C12
alcohols, although tertiary, react faster with standard acylating
reagents than the C3 alcohol.17,18,28 Building oﬀ Inoue’s
ﬁndings that cyclic boronates can be used to strategically
protect the alcohols of ryanodol,25 the ring fusion diol of 12
was converted to the dioxaborinane by treatment with
methylboronic acid. Subsequent LiBH4-mediated 1,2-reduction
of 13 furnished the C3 alcohol with high diastereoselectivity.
We initially explored a route involving hydrogenation of the
isopropenyl group prior to acylation; however, poor reactivity
was observed under a variety of conditions using pyrrole-2-
carboxylic acid derivatives.
Instead, we turned to the acylation of 14, under the
hypothesis that the smaller steric proﬁle of the adjacent C(sp2)
isopropenyl group (relative to isopropyl) would render the C3
alcohol more accessible. Whereas several standard acylating
reagents derived from pyrrole-2-carboxylic acid failed to deliver
16 (see the Supporting Information), we were pleased to ﬁnd
that deprotonation of alcohol 14 with sodium hydride (NaH)
at 0 °C, followed by addition of 2,2,2-trichloro-1-(1H-pyrrol-2-
yl)ethan-1-one (15), aﬀorded the desired pyrrole ester 16 in
57% isolated yield (structure veriﬁed by X-ray crystallog-
raphy).30
Figure 2. Synthetic considerations. (A) Oxidation products 7 and 8,
each accessible from 6 by modiﬁcation of the SeO2 reaction
conditions, can be elaborated to either (+)-ryanodine (1) or (+)-20-
deoxyspiganthine (3), respectively. (B) Retrosynthetic analysis for 1
and 3. Key strategic innovation is to directly incorporate pyrrole-2-
carboxylate ester (as in 10) prior to reductive cyclization.
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Having incorporated the key pyrrole-2-carboxylate ester, 16
was elaborated to anhydroryanodine (18) in two steps. First,
the methyl boronate of 16 was cleaved with aqueous KHF2 in
methanol to aﬀord diol 17, which was then subjected to H2 and
Pd(OH)2/C to simultaneously reduce the terminal oleﬁn and
remove the benzyloxymethyl ether (BOM) groups, providing
18 in 90% yield. The structural assignment of 18 was conﬁrmed
by single crystal X-ray diﬀraction.
With access to 18, completion of the synthesis required
epoxidation and reductive ring closure. Unfortunately, mild
epoxidation reagents (e.g., 3-chloroperoxybenzoic acid
(mCPBA)) returned starting material, whereas more reactive
reagents (e.g., triﬂuoroperacetic acid) resulted in decomposi-
tion, likely due to undesired reactivity at the pyrrole. In an
attempt to harness the directing ability of the proximal C4 and
C12 alcohols, we turned to vanadyl-mediated epoxidation
conditions; however, no reaction was observed. We hypothe-
sized that competing, nonproductive coordination of vanadium
by the C6, C4, and C12 alcohols was precluding formation of
the active epoxidation species, and therefore investigated the
reaction of a partially protected intermediate. Chemoselective
hydrogenation of the terminal alkene of 17 was achieved using
H2 with PtO2, and, to our delight, exposure of 19 to
VO(acac)2/TBHP in benzene at room temperature delivered
epoxide 20 in 60% yield. Subsequent hydrogenolytic
deprotection of the BOM protecting groups under previously
developed conditions provided anhydroryanodine epoxide 21.
The ﬁnal step of the synthesis required formation of the C1−
C15 bond through a reductive cyclization step, in analogy to
the chemistry developed for the synthesis of (+)-ryanodol (4).
Although submission of 21 to Li/NH3 indeed aﬀected the
desired bond construction, 4 was the only product recovered
under these conditions, highlighting the additional challenge
presented by the lability of the ester in 21 (Table 1, entry 1).
Hypothesizing that deprotonation of the pyrrole-2-carbox-
ylate ester would render it less susceptible to cleavage by
reduction or aminolysis processes, 21 was ﬁrst treated with
LDA (5.9 equiv), and the resulting solution was added to a
mixture of Li0 in NH3, which provided 1 (20% yield) in a 1:2
ratio with 4 (Table 1, entry 2).
Reactions conducted with 10 equiv of LDA under otherwise
identical conditions resulted in recovery of starting material,
presumably due to deprotonation of the lactone, which
precludes ketyl formation (entry 3). Concerned that formation
of 4 under the Li/NH3 conditions results in part from
aminolysis of the ester, we investigated soluble single electron
reductants that could be used in solvents other than liquid
ammonia. Gratifyingly, when lithium naphthalenide (LiNap) in
THF was used, a 2:1 ratio of 21 to 1 was produced, without
detectable amounts of 4 (entry 4). The reaction could be
further improved by employing the more reducing lithium di-
Scheme 1. Chemical Synthesis of (+)-Ryanodine
Table 1. Evaluation of Reductive Cyclization Conditions
entry conditions 21:4:1a
yield of
1 (%)b
1 Li/NH3, THF, −78 °C 0:1:0
2 LDA (5.9 equiv), THF, −78 °C; then
Li/NH3, −78 °C
0:2:1 20
3 LDA (10.0 equiv), THF, −78 °C; then
Li/NH3, −78 °C
1:0:0
4 LiNap (4.5 equiv), THF, −78 °C 2:0:1
5 LiDBB (3.5 equiv), THF, −78 °C 1:0:4 64
aDetermined by 1H NMR spectroscopy. bIsolated yield of 1 after
puriﬁcation by silica gel preparative TLC.
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tert-butylbiphenylide (LiDBB), which aﬀorded 1 in 64%
isolated yield (entry 5). Moreover, the step count of the
synthesis could be reduced by performing the reductive ring
closure on BOM protected epoxide 20, which smoothly
undergoes C−C bond formation and BOM deprotection to
provide (+)-1 in 65% yield. Using this 18-step route, we have
prepared >60 mg of synthetic (+)-ryanodine to date and were
able to use this material to solve the ﬁrst X-ray crystal structure
of the molecule.
Having established a concise route to (+)-1, we turned to the
synthesis of (+)-20-deoxyspiganthine (3). Preliminary bio-
logical studies reported by the isolation team determined that
this compound also exhibits potent activity in cardiac tissue
assays of RyR function. Given the improved yields for the
formation of 8 in the SeO2-mediated oxidation/triﬂation of
tetracycle 6 (Figure 2A), 3 could be an appealing starting point
for the future development of RyR probe molecules. Starting
with tetracycle 22 (which is prepared from 8 by Stille cross-
coupling), the C12 alcohol was protected as a TMS ether and
the ketone was reduced with LiBH4 to give alcohol 23 (Scheme
2). Unfortunately, eﬀorts to acylate the C3 alcohol under the
previously described conditions resulted in rapid TMS
deprotection and very low yields of the desired ester (10−
15%). Ultimately we found that treatment of 23 with 2 equiv of
potassium bis(trimethylsilyl)amide (KHMDS) followed by
addition of a solution of TBS-protected pyrrole 24 provided
ester 25, which had also undergone chlorination at C14 (5.8:1
dr). The undesired chlorination reaction could, in principle, be
mitigated by using less KHMDS; however, under these
conditions translactonization by the C3 alcohol precedes
esteriﬁcation. Thus, enolization of the lactone prevents
translactonization, but also results in α-chlorination at temper-
atures required to observe good levels of reactivity.
Undeterred by this result, dechlorination of 25 was
accomplished without complication using tris(trimethylsilyl)-
silane ((TMS)3SiH) and the low-temperature initiator
triethylborane (Et3B) to give 26. Deprotection of both silyl
groups, hydrogenation of the terminal alkene, and hydroxyl-
directed epoxidation of the remaining tetrasubstituted alkene
furnished 27. Treatment of 27 with 10 equiv of freshly prepared
LiDBB resulted in cyclization and deprotection of both BOM
groups, aﬀording (+)-20-deoxyspiganthine (3) in 58% yield.
The structure of 3 was unambiguously conﬁrmed by single
crystal X-ray diﬀraction. At 19 steps, this is the ﬁrst total
synthesis of a spiganthine-type natural product. It is notable
that, with the exception of the C3-acylation reaction, no
reoptimization was required to translate the synthesis of 1 to 3,
demonstrating the versatility of this strategy.
In summary, the chemical syntheses of (+)-ryanodine (1)
and (+)-20-deoxyspiganthine (3) were achieved in 18 and 19
steps, respectively. A key discovery is that anhydroryanodol
derivatives (and related C4-deoxy analogues) that possess
C13−C18 unsaturation can be acylated directly to incorporate
the crucial pyrrole-2-carboxylate ester. This represents a
practical solution to one of the key challenges encountered in
previous eﬀorts to prepare ryanodine,25 which should allow for
the incorporation of an array of ester substituents at C3 for
future SAR studies. In addition, we determined that a LiDBB-
mediated reductive cyclization can be used to forge the ﬁnal
C1−C15 bond with the pyrrole ester intact. Taken together,
these discoveries provide a synthetic platform that will enable
the synthesis of a variety of natural and designed ryanoids.
Ongoing studies in our laboratory seek to leverage this
chemistry for the development of synthetic, molecular probes
that can aid the study of RyR dysfunction and Ca2+ ion
channel-based diseases.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acscentsci.6b00361.
Experimental procedures and characterization data (1H
and 13C NMR, HRMS, FTIR) for all new compounds
(PDF)
Crystallographic information for 18 (CIF)
Crystallographic information for 16 (CIF)
Crystallographic information for 1 (CIF)
Crystallographic information for 3 (CIF)
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: reisman@caltech.edu.
ORCID
Chen Xu: 0000-0002-3222-459X
Sarah E. Reisman: 0000-0001-8244-9300
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
The Caltech Center for Catalysis and Chemical Synthesis is
gratefully acknowledged for access to analytical equipment. We
thank Dr. Michael Takase and Larry Henling for acquiring the
X-ray diﬀraction data and Julie Hofstra for solving the
structures of compounds 1, 3, 16, and 18. Fellowship support
was provided by the Shenzhen UV-ChemTech Inc. (post-
Scheme 2. Chemical Synthesis of (+)-20-Deoxyspiganthine
ACS Central Science Research Article
DOI: 10.1021/acscentsci.6b00361
ACS Cent. Sci. 2017, 3, 278−282
281
doctoral fellowship to C.X.) and the NIH (training grant
5T32GM007616-37 to A.H.). S.E.R. is an American Cancer
Society Research Scholar and Heritage Medical Research
Institute investigator. Financial support from the NIH
(NIGMS RGM097582-01, R35GM118191-01), Eli Lilly, and
Novartis is gratefully acknowledged.
■ REFERENCES
(1) Lanner, J. T.; Georgiou, D. K.; Joshi, A. D.; Hamilton, S. L.
Ryanodine Receptors: Structure, Expression, Molecular Details, and
Function in Calcium Release. Cold Spring Harbor Perspect. Biol. 2010,
2, a003996.
(2) Ryanodine Receptors: Structure, Function and Dysfunction in Clinical
Disease; Wehrens, X. H. T., Marks, A. R., Eds.; Springer US: Boston,
2005.
(3) Lanner, J. T. Ryanodine Receptor Physiology and Its Role in
Diseasec. In Calcium Signaling, Advances in Experimental Medicine and
Biology; Islam, S., Ed.; Springer: Dordrecht, 2012.
(4) McCarthy, T. V.; Quane, K. A.; Lynch, P. J. Ryanodine receptor
mutations in malignant hyperthermia and central core disease. Hum.
Mutat. 2000, 15, 410−417.
(5) Laitinen, P. J.; Brown, K. M.; Piippo, K.; Swan, H.; Devaney, J.
M.; Brahmbhatt, B.; Donarum, E. A.; Marino, M.; Tiso, N.; Viitasalo,
M.; Toivonen, L.; Stephan, D. A.; Kontula, K. Mutations of the cardiac
ryanodine receptor (RyR2) gene in familial polymorphic ventricular
tachycardia. Circulation 2001, 103, 485−490.
(6) Kelliher, M.; Fastbom, J.; Cowburn, R. F.; Bonkale, W.; Ohm, T.
G.; Ravid, R.; Sorrentino, V.; O’Neill, C. Alterations in the ryanodine
receptor calcium release channel correlate with Alzheimer’s disease
neurofibrillary and beta-amyloid pathologies. Neuroscience 1999, 92,
499−513.
(7) Bruno, A. M.; Huang, J. Y.; Bennett, D. A.; Marr, R. A.; Hastings,
M. L.; Stutzmann, G. E. Altered ryanodine receptor expression in mild
cognitive impairment and Alzheimer’s disease. Neurobiol. Aging 2012,
33, 1001.e1−1001.e6.
(8) Pessah, I. N.; Waterhouse, A. L.; Casida, J. E. The calcium-
ryanodine receptor complex of skeletal and cardiac muscle. Biochem.
Biophys. Res. Commun. 1985, 128, 449−456.
(9) Inui, M.; Saito, A.; Fleischer, S. Isolation of the ryanodine
receptor from cardiac sarcoplasmic reticulum and identity with the feet
structures. J. Biol. Chem. 1987, 262, 15637−15642.
(10) Rogers, E. F.; Koniuszy, F. R.; Shavel, J.; Folkers, K. Plant
Insecticides. 1. Ryanodine, a new alkaloid from Ryania speciosa Vahl. J.
Am. Chem. Soc. 1948, 70, 3086−3088.
(11) Wiesner, K.; Valenta, Z.; Findlay, J. A. Structure of ryanodine.
Tetrahedron Lett. 1967, 8, 221.
(12) Srivastava, S. N.; Przybylska, M. The molecular structure of
ryanodol-p-bromo benzyl ether. Can. J. Chem. 1968, 46, 795−797.
(13) Wiesner, K. The structure of ryanodine. Adv. Org. Chem. 1972,
8, 295−316.
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(18) Beĺanger, A.; Berney, D. J. F.; Borschberg, H. J.; Brousseau, R.;
Doutheau, A.; Durand, R.; Katayama, H.; Lapalme, R.; Leturc, D. M.;
Liao, C. C.; MacLachlan, F. N.; Maffrand, J. P.; Marazza, F.; Martino,
R.; Moreau, C.; Saint-Laurent, L.; Saintonge, R.; Soucy, P.; Ruest, L.;
Deslongchamps, P. Total Synthesis of Ryanodol. Can. J. Chem. 1979,
57, 3348−3354.
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